Thrombophilia and fetal loss

Area of Science:

• Obstetrics and Gynecology
• Hematology
• Immunology

Background:

• Antiphospholipid syndrome (APS) is an acquired autoimmune thrombophilia linked to pregnancy complications.
• Heritable thrombophilic disorders, including activated protein C resistance, factor V Leiden mutation, and hyperhomocysteinemia, are increasingly recognized.
• Recent data suggest a link between heritable thrombophilia and adverse pregnancy outcomes such as fetal loss and pre-eclampsia.

Purpose of the Study:

• To review the potential pathogenetic mechanisms connecting heritable thrombophilia with fetal loss and pre-eclampsia.
• To evaluate therapeutic strategies for preventing fetal loss in women diagnosed with thrombophilia.

Main Methods:

• Literature review of studies on antiphospholipid syndrome and heritable thrombophilia.
• Analysis of pathogenetic mechanisms for thrombosis in pregnancy.
• Evaluation of reported therapeutic interventions for pregnancy complications in thrombophilic patients.

Main Results:

• Antiphospholipid syndrome is a known risk factor for placental vascular pathologies and recurrent fetal loss.
• Heritable thrombophilic states are associated with an elevated risk of fetal loss and pre-eclampsia.
• Various therapeutic regimes are being reported for the prevention of fetal loss in women with thrombophilia.

Conclusions:

• Both acquired (APS) and heritable thrombophilias pose significant risks during pregnancy.
• Understanding the pathogenetic links is crucial for developing effective prevention and treatment strategies.
• Further research into therapeutic regimes is warranted to improve pregnancy outcomes for women with thrombophilia.